Flindr Therapeutics

About Flindr Therapeutics

Flindr Therapeutics develops a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer. They utilize their ImmunoGram Drug Discovery Engine to discover novel targets in both cancer cells and immune cells, focusing on disruptive cancer science for transformative treatments.

Products & Services

Small Molecule Inhibitors:First-in-class inhibitors for precision oncology, targeting novel drug targets in cancer and immune cells.

RNF31 Inhibitors:Inhibitors targeting oncogenic driver RNF31 for cancer treatment.

Specialties

Small Molecule Therapeutics Precision Oncology Novel Drug Target Identification ImmunoGram Drug Discovery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 21400056 MR: - FA: €20 million FAN: 21400056	D: 2024-04-24 FD: 2024-04-24	8 investors

Series A Latest

2024-04-24

$21.4M

8 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Daniel Peeper

Founder

C

Christian Blank

Founder

M

Maarten Ligtenberg

Founder / Chief Executive Officer

R

Rudi Beyaert

Professor

J

Jac Wijkmans

Chief Scientific Officer

A

Allard Kaptein

Chairman

View 8 more team members with Pro

Unlock Full Team Directory

Recent News